

8/17  
5,7-dihydro-7-methyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-7-ethyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[2-[1-(2-chloro-5-thiophenemethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[2-[1-(2-methyl-4-thiazolemethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

3-[2-[1-(3-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;


3-[2-[1-(4-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

6,8-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-7H-pyrrolo[5,4-g]-1,2-benzisoxazol-7-one; and


5,7-dihydro-3-[2-(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one.

13. (Twice amended) A pharmaceutical composition for use in the treatment of an age-related behavior disorder in a companion animal comprising a compound of Formula 1:



Formula 1

wherein  $R^1$  and  $R^2$  are each independently selected from the group consisting of hydrogen;  $(C_1-C_6)$ alkoxy; benzyloxy; phenoxy; hydroxy; phenyl; benzyl; halo; nitro; cyano;  $-COR^5$ ;  $-COOR^5$ ;  $CONHR^5$ ;  $-NR^5R^6$ ;  $-NR^5COR^6$ ;  $-OCONR^5R^6$ ;  $-NHCOOR^5$ ;  $(C_1-C_6)$  alkyl which may be substituted with from 1 to 3 fluorine atoms;  $SO_pCH_2$ -phenyl or  $SO_p(C_1-C_6)$  alkyl, wherein p is 0, 1 or 2; pyridylmethyloxy or thienylmethyloxy; 2-oxazolyl; 2-thiazolyl; and benzenesulfonamide; wherein the phenyl moieties of said phenoxy, benzyloxy, phenyl, benzyl and benzenesulfonamide groups, the pyridyl and thienyl moieties of said pyridylmethyloxy or thienylmethyloxy groups, and the oxazolyl and thiazolyl moieties of said 2-oxazolyl and 2-thiazolyl groups may be substituted with 1 or 2 substituents independently selected from the group consisting of halo,  $(C_1-C_4)$  alkyl, trifluoromethyl,  $(C_1-C_4)$  alkoxy, cyano, nitro and hydroxy; or  $R^1$  and  $R^2$  are attached to adjacent carbon atoms and form, together with the carbon atoms to which they are attached, a group of Formula 2:



Formula 2

wherein  $R^3$  is hydrogen or  $(C_1-C_6)$  alkyl; J is oxygen, sulfur or  $NR^4$ ;  $R^4$  is hydrogen or  $(C_1-C_4)$  alkyl; and Q is oxygen, sulfur, NH,  $CHCH_3$ ,  $C(CH_3)_2$ ,  $-CH=CH-$ , or  $(CH_2)_1$  wherein 1 is an integer from 1 to 3;

X is oxygen or sulfur;


Y is  $(CH_2)_m$ ,  $CH=CH(CH_2)-$ , or  $-O(CH_2)_m-$ , wherein n is an integer from 0 to 3, and m is an integer from 1 to 3;

*Cont*  
 $R^5$  and  $R^6$  are each independently selected from the group consisting of hydrogen,  $(C_1-C_6)$  alkyl, phenyl, and benzyl, wherein the phenyl moieties of said phenyl and benzyl groups may be substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, chloro, bromo, iodo,  $(C_1-C_4)$  alkyl, trifluoromethyl,  $(C_1-C_4)$  alkoxy, cyano, nitro and hydroxy, or

$NR^5R^6$  together form a 4 or 5 membered ring wherein one atom of the ring is nitrogen and the others are carbon, oxygen or nitrogen; or  $NR^5COR^6$  together form a 4 or 5 membered lactam ring;

L is phenyl, phenyl- $(C_1-C_6)$  alkyl, cinnamyl or pyridylmethyl, wherein the phenyl moieties of said phenyl and phenyl- $(C_1-C_6)$  alkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of  $(C_1-C_6)$  alkyl,  $(C_1-C_6)$  alkoxy,  $(C_1-C_4)$  alkoxycarbonyl,  $(C_1-C_6)$  alkylcarbonyl,  $-OCONR^5R^6$ ,  $-NHCOOR^5$ , and

halo; or L is a group of Formula 3:



Formula 3

C2 cont

wherein b is an integer from 1 to 4; R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>4</sub>) alkyl, halo, and phenyl; E and F are independently -CH- or nitrogen; and G is oxygen, sulfur or NR<sup>4</sup>, with the proviso that when E and F are both nitrogen, one of R<sup>9</sup> and R<sup>10</sup> is absent; and R<sup>7</sup> and R<sup>8</sup> are independently selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>6</sub>) alkyl, (C<sub>1</sub>-C<sub>6</sub>) alkoxy, (C<sub>1</sub>-C<sub>6</sub>) alkoxycarbonyl, (C<sub>1</sub>-C<sub>6</sub>) alkylcarbonyl, and (C<sub>1</sub>-C<sub>6</sub>) alkoxy, with the proviso that said (C<sub>1</sub>-C<sub>6</sub>) alkoxy is not attached to a carbon that is adjacent to a nitrogen; or a pharmaceutically acceptable salt of solvate thereof, and a pharmaceutically acceptable carrier.

C3

17. (Amended) A dosage form of a compound of Claim 1 for use in the treatment of an age-related behavioral disorder in a companion animal.

19. (Twice amended) The dosage form of Claim 18 wherein the compound of Claim 1 is selected from the group consisting of:

C4

5,7-dihydro-7-methyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-7-ethyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[2-[1-(2-chloro-5-thiophenemethyl)-4-piperidinyl]ethyl]-  
6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[2-[1-(2-methyl-4-thiazol-5-ylmethyl)-4-piperidinyl]ethyl]-  
6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

3-[2-[1-(3-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-  
pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

3-[2-[1-(4-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-  
pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]-6H-  
pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

6,8-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-7H-pyrrolo[5,4-  
g]-1,2-benzisoxazol-7-one; and

5,7-dihydro-3-[2-(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-pyrrolo[4,5-  
f]-1,2-benzisoxazol-6-one.

20. (Twice amended) The dosage form of Claim 19 wherein the  
compound of Claim 1 is 5,7-dihydro-3-[2-(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-  
pyrrolo[4,5-f]-1,2-benzisoxazol-6-one.

21. (Amended) The dosage form of claim 20 wherein said dosage form  
comprises from about 0.001 mg to about 100 mg of the compound of Claim 1.